The IMI Networking event - Pharma meets Academia is organized by Luxinnovation and its partners, Luxembourg Centre for Systems Biomedicine (LCSB), Integrated Biobank of Luxembourg (IBBL), Laboratoire national de santé (LNS) and Luxembourg Institute of Health (LIH). The meeting will take place on 14 December 2018, at the Laboratoire national de sante, Rue Louis Rech 5,
Dudelange, Luxembourg.
The HARMONY Alliance is represented by Project Coordinator Jesús María Hernández Rivas of the Research group in Molecular Cytogenetics, IBSAL, Spain.
The event will focus on the optimal use of medical data generated through current and future projects of the Innovative Medicines Initiative (IMI). Participants will have a chance to exchange best practices and meet representatives from the pharmaceutical industry, biotech companies, academia and research infrastructures to forge new partnerships in medical research.
The Innovative Medicines Initiative (IMI) is a unique partnership between the European Union and the European pharmaceutical industry that funds research projects based on direct industry needs. IMI facilitates open collaboration in research to advance the development of, and accelerate patient access to, personalised medicines for the health and wellbeing of all, especially in areas of unmet medical need.
Luxembourg presents an exciting portfolio of health-related research, infrastructure and innovation through continuous investment in the ecosystem, and is regarded as a perfect testbed to implement and pilot innovative health solutions in an entire healthcare system.
The conference will highlight several ongoing IMI projects - such as HARMONY - and analyse how the long-term use of data generated in this field can be made secure, sustainable and of the best benefit to the patient. It will also be an opportunity to discuss future priorities of IMI and network with potential collaboration partners for forthcoming projects. Furthermore, there will be a session on IMI management and grant writing to prepare audiences for future calls.
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
